Evidence brief for 29 May to 04 June 2021
For the period of 29 May to 04 June 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 29 May to 04 June 2021
HTAC Guidance for the General Public: COVID-19 Vaccine Moderna
The HTAC recommends the emergency use of COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the prevention of COVID-19 for persons aged 18 and older. COVID-19 Vaccine Moderna under Emergency Use The emergency use authorization of the Food and Drug Administration (FDA) (dated 07 May 2021) allows for timely access of COVID-19 vaccines for continue reading : HTAC Guidance for the General Public: COVID-19 Vaccine Moderna
HTAC Guidance for Health Care Providers: COVID-19 Vaccine Moderna
The HTAC recommends the emergency use of COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the prevention of COVID-19 for persons aged 18 and older. Introduction (nature and purpose of EUA) The Food and Drug Administration (FDA) issues emergency use authorization (EUA) for vaccines and drugs during public health emergencies. This authorization expedites the continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Moderna
HTAC Guidance for Health Care Providers : COVID-19 Vaccine Janssen
The HTAC recommends the emergency use of Janssen Ad26.COV2.S (COVID-19) Vaccine to prevent COVID-19 for persons aged 18 and older. Introduction (nature and purpose of EUA) The Food and Drug Administration (FDA) issues emergency use authorization (EUA) for vaccines and drugs during public health emergencies. This authorization expedites the availability of interventions for affected populations. continue reading : HTAC Guidance for Health Care Providers : COVID-19 Vaccine Janssen